Drug profile · INN
umeclidinium
INCRUSE ELLIPTA
umeclidinium (INCRUSE ELLIPTA) is a muscarinic acetylcholine receptor m3 antagonist. Associated with GlaxoSmithKline.
EMA: approved TGA: approved Respiratory system (R03) R03BB07
Patents linked 0
Pipeline programs 1
News articles 0
Drug details — umeclidinium
- Class
- Respiratory system (R03)
- Route
- —
- Patents
- 0
- Programs
- 1
- Data quality
- 0.83
Quick answer
umeclidinium (INCRUSE ELLIPTA) is a muscarinic acetylcholine receptor m3 antagonist. Associated with GlaxoSmithKline.
Key facts
INN umeclidinium
Brand INCRUSE ELLIPTA
Mechanism Muscarinic acetylcholine receptor M3 antagonist
Therapeutic class Respiratory system (R03)
ATC code R03BB07
Originator GlaxoSmithKline
Mechanism of action
Muscarinic acetylcholine receptor M3 antagonist
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is umeclidinium?
umeclidinium (INCRUSE ELLIPTA) is a muscarinic acetylcholine receptor m3 antagonist. Associated with GlaxoSmithKline.
What is the brand name for umeclidinium?
INCRUSE ELLIPTA is a marketed brand name for umeclidinium. Check FDA Drugs@FDA for the current US label holder and prescribing information.